Lise Lund Kjems
Geen lopende functies
Vermogen: 21 828 $ op 31-05-2024
Loopbaan van Lise Lund Kjems
Eerdere bekende functies van Lise Lund Kjems
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| CYCLO THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 27-09-2021 | 01-04-2023 |
| ALBIREO PHARMA, INC. | Corporate Officer/Principal | - | - |
Opleiding van Lise Lund Kjems
| University of Copenhagen | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 3 |
| Denemarken | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CYCLO THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
- Beurs
- Insiders
- Lise Lund Kjems
- Ervaring
